HomeCompareLVTX vs BTI

LVTX vs BTI: Dividend Comparison 2026

LVTX yields 114.94% · BTI yields 5.38%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 LVTX wins by $7.01M in total portfolio value
10 years
LVTX
LVTX
● Live price
114.94%
Share price
$1.74
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$7.05M
Annual income
$2,599,161.52
Full LVTX calculator →
BTI
BTI
● Live price
5.38%
Share price
$58.47
Annual div
$3.15
5Y div CAGR
11.3%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$37.7K
Annual income
$2,786.64
Full BTI calculator →

Portfolio growth — LVTX vs BTI

📍 LVTX pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodLVTXBTI
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, LVTX + BTI cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
LVTX pays
BTI pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

LVTX
Annual income on $10K today (after 15% tax)
$9,770.11/yr
After 10yr DRIP, annual income (after tax)
$2,209,287.29/yr
BTI
Annual income on $10K today (after 15% tax)
$457.40/yr
After 10yr DRIP, annual income (after tax)
$2,368.64/yr
At 15% tax rate, LVTX beats the other by $2,206,918.65/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of LVTX + BTI for your $10,000?

LVTX: 50%BTI: 50%
100% BTI50/50100% LVTX
Portfolio after 10yr
$3.54M
Annual income
$1,300,974.08/yr
Blended yield
36.72%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on BTI right now

LVTX
Analyst Ratings
2
Buy
4
Hold
Consensus: Hold
Price Target
$3.75
+115.5% upside vs current
Range: $1.50 — $6.00
Altman Z
-4.7
Piotroski
1/9
BTI
Analyst Ratings
12
Buy
4
Hold
2
Sell
Consensus: Buy
Price Target
$40.00
-31.6% upside vs current
Range: $40.00 — $40.00
Altman Z
2.1
Piotroski
7/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

LVTX buys
0
BTI buys
0
No recent congressional trades found for LVTX or BTI in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricLVTXBTI
Forward yield114.94%5.38%
Annual dividend / share$2.00$3.15
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%11.3%
Portfolio after 10y$7.05M$37.7K
Annual income after 10y$2,599,161.52$2,786.64
Total dividends collected$6.38M$14.3K
Payment frequencyquarterlyquarterly
SectorStockConsumer Staples
Analyst consensusHoldBuy
Analyst price target$3.75$40.00

Year-by-year: LVTX vs BTI ($10,000, DRIP)

YearLVTX PortfolioLVTX Income/yrBTI PortfolioBTI Income/yrGap
1← crossover$22,194$11,494.25$11,299$598.92+$10.9KLVTX
2$47,590$23,841.72$12,794$703.91+$34.8KLVTX
3$98,699$47,777.67$14,518$829.07+$84.2KLVTX
4$198,214$92,606.18$16,513$978.64+$181.7KLVTX
5$385,900$173,811.71$18,827$1,157.84+$367.1KLVTX
6$729,168$316,254.64$21,518$1,373.12+$707.6KLVTX
7$1,338,687$558,477.43$24,657$1,632.46+$1.31MLVTX
8$2,390,633$958,237.97$28,329$1,945.74+$2.36MLVTX
9$4,157,254$1,599,276.16$32,637$2,325.33+$4.12MLVTX
10$7,047,423$2,599,161.52$37,708$2,786.64+$7.01MLVTX

LVTX vs BTI: Complete Analysis 2026

LVTXStock

LAVA Therapeutics N.V., a clinical-stage immuno-oncology company, focuses on developing cancer treatments. The company, through its Gammabody platform, develops a portfolio of novel bispecific antibodies to engage and leverage the potency and precision of gamma delta T cells to elicit an anti-tumor immune response and enhance outcomes for cancer patients. Its lead clinical-stage candidates are LAVA-051, which is in Phase 1/2a clinical trial for blood cancers, including chronic lymphocytic leukemia, multiple myeloma, and acute myeloid leukemia; and LAVA-1207 that is in Phase 1/2a clinical trial for metastatic castration-resistant prostate cancer. The company is also developing other Gammabody drug candidates, which include LAVA-1223, which targets the epidermal growth factor receptor (EGFR) for the treatment of selected solid tumors, as well as LAVA-1266 and LAVA-1278, which are preclinical candidates for the treatment of various hematologic malignancies. LAVA Therapeutics N.V. has a research collaboration and license agreement with Janssen Biotech, Inc. for the potential discovery and development of multi-specific antibody products that are directed to a specified target in various fields of use. The company was incorporated in 2016 and is headquartered in Utrecht, the Netherlands.

Full LVTX Calculator →

BTIConsumer Staples

British American Tobacco p.l.c. provides tobacco and nicotine products to consumers in the Americas, Europe, the Asia-Pacific, the Middle East, Africa, and the United States. It offers vapour, heated, and modern oral nicotine products; combustible cigarettes; and traditional oral products, such as snus and moist snuff. The company provides its products under the Vuse, glo, Velo, Grizzly, Kodiak, Dunhill, Kent, Lucky Strike, Pall Mall, Rothmans, Newport, Natural American Spirit, and Camel brands. The company distributes its products to retail outlets. British American Tobacco p.l.c. was founded in 1902 and is based in London, the United Kingdom.

Full BTI Calculator →
📬

Get this LVTX vs BTI comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

LVTX vs SCHDLVTX vs JEPILVTX vs OLVTX vs KOLVTX vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.